See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Democratic Party
Republican Party
Social Media
US Politics
Tariffs
Education
Eid
Artificial Intelligence
Donald Trump
Baseball
Senate
Published • loading... • Updated

Breakthrough Eye Treatment Shows 21% Success Rate in Phase 3 Trial for Night Vision Problems

Summary by stocktitan.net
New clinical data reveals Opus Genetics' eye drops significantly improve dim light vision, with 21% efficacy at Day 15. Strong results for post-LASIK patients spark treatment potential.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
Eyewire+Eyewire+

Opus Genetics Presents Phentolamine Ophthalmic Solution 0.75% Improves Visual Acuity in Patients with Dim Light Disturbances, World Cornea Congress IX

Opus Genetics, Inc. shared the positive findings of their Phentolamine Ophthalmic Solution 0.75% to improve visual acuity in patients with dim light disturbances last week at the World Cornea Congress IX in Washington D.C. The results are from the company’s LYNX-1 phase 3 clinical trial. Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. It is currently being investi…

Read Full Article
csimarket.comcsimarket.com

# Opus Genetics Unveils Promising Phase 3 Results for Phentolamine Ophthalmic Solution at World Cornea Congress...

'RESEARCH TRIANGLE PARK, N.C. '' March 21, 2025' '' In a noteworthy advancement in the realm of ophthalmic medicine, Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company that specializes in the development of gene therapies for inherited retinal diseases (IRDs) and other ophthalmic disorders, has announced the presentation of significant findings from the LYNX-1 Phase 3 study on Phentolamine Ophthalmic Solution 0.75%. This g…

Read Full Article
stocktitan.netstocktitan.net

Breakthrough Eye Treatment Shows 21% Success Rate in Phase 3 Trial for Night Vision Problems

New clinical data reveals Opus Genetics' eye drops significantly improve dim light vision, with 21% efficacy at Day 15. Strong results for post-LASIK patients spark treatment potential.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Friday, March 21, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal